In 1992, graduate student Yasumasa Ishida discovered PD-1, marking the beginning of a journey that would make this molecule a ...

Recent breakthroughs in understanding the prostaglandin D2 (PGD2) receptor 1 (DP1) are paving the way for innovative ...

Instil Bio eyes key NSCLC catalyst with Phase 2 China data in 2H 2025 and a distinct U.S. strategy. Learn why AXN-2510 stands ...

The global ablation technology market was valued at US$ 6.82 billion in 2024 and is projected to reach US$ 16.74 billion by ...

Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a ...

Golidocitinib combined with PD-1 antibodies achieved a 44.3% response rate in NSCLC patients post anti-PD-1 therapy progression. The combination therapy showed a complete response rate of 23.9% and a ...

PD-1 is a cell-surface receptor that resides on T and B cells, keeping immune cells from attacking other cells within the body. This prevents autoimmune diseases but also prevents the immune system ...

Since its discovery in the 1990s, “programmed cell death protein 1,” or PD-1, has been regarded as a leading target in cancer treatments. A “checkpoint” receptor that often resides on the surface of ...

HONG KONG, Dec. 4, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective, open-label, single-arm, multi-center phase Ib/II clinical study ...

Our study reveals that the PD-1 receptor functions optimally as dimers ... other findings was that a single change in the amino acid structure of the transmembrane segment can act to either ...